The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | “Sequential triple-T” therapy for CLL
“Sequential triple-T” therapy is a regimen consisting of tailored and targeted treatment aiming for total eradication of minimal residual disease (MRD). Here, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, provides an overview of the Phase II CLL2-BIO study (NCT02689141) of bendamustine, ofatumumab and ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL) patients. Dr Eichhorst highlights the promising results of this sequential regimen. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
